Quotient (QTNT) Stock Rating Lowered by BidaskClub

Share on StockTwits

BidaskClub downgraded shares of Quotient (NASDAQ:QTNT) from a hold rating to a sell rating in a research report report published on Tuesday morning, BidAskClub reports.

QTNT has been the topic of several other reports. Jefferies Financial Group increased their price target on Quotient from $11.00 to $13.50 and gave the company a buy rating in a report on Tuesday, March 5th. ValuEngine cut Quotient from a strong-buy rating to a buy rating in a report on Friday, April 19th. Finally, Zacks Investment Research raised Quotient from a sell rating to a hold rating in a report on Wednesday, May 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. The company has an average rating of Hold and an average target price of $11.75.

QTNT traded down $0.15 during trading on Tuesday, hitting $9.16. 2,643 shares of the company’s stock traded hands, compared to its average volume of 335,731. The company has a current ratio of 6.87, a quick ratio of 6.05 and a debt-to-equity ratio of 4.95. Quotient has a 12-month low of $4.60 and a 12-month high of $11.15. The company has a market cap of $602.19 million, a price-to-earnings ratio of -4.55 and a beta of 1.25.

In related news, President Edward Farrell sold 22,500 shares of the firm’s stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $8.67, for a total value of $195,075.00. Following the transaction, the president now directly owns 2,133 shares of the company’s stock, valued at approximately $18,493.11. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 17.40% of the stock is currently owned by company insiders.

A number of institutional investors have recently made changes to their positions in QTNT. Lombard Odier Asset Management USA Corp increased its stake in Quotient by 4.0% in the 1st quarter. Lombard Odier Asset Management USA Corp now owns 260,000 shares of the company’s stock worth $2,343,000 after buying an additional 10,000 shares in the last quarter. Morgan Stanley increased its stake in Quotient by 151.1% in the 1st quarter. Morgan Stanley now owns 1,772,678 shares of the company’s stock worth $15,972,000 after buying an additional 1,066,682 shares in the last quarter. M&T Bank Corp increased its stake in Quotient by 113.6% in the 1st quarter. M&T Bank Corp now owns 21,829 shares of the company’s stock worth $197,000 after buying an additional 11,609 shares in the last quarter. SEI Investments Co purchased a new stake in Quotient in the 1st quarter worth $680,000. Finally, Essex Investment Management Co. LLC purchased a new stake in Quotient in the 1st quarter worth $1,152,000. 66.32% of the stock is currently owned by institutional investors.

About Quotient

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.

Read More: Different Options Trading Strategies

Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.